Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Susana Arrigain to Renal Insufficiency, Chronic

This is a "connection" page, showing publications Susana Arrigain has written about Renal Insufficiency, Chronic.

 
Connection Strength
  
 
 
2.638
  
  1. Augustine JJ, Liaqat A, Arrigain S, Schold JD, Poggio ED. Performance of estimated glomerular filtration rate equations in Black living kidney donor candidates. Clin Transplant. 2024 01; 38(1):e15198.
    View in: PubMed
    Score: 0.141
  2. Cholin L, Ashour T, Mehdi A, Taliercio JJ, Daou R, Arrigain S, Schold JD, Thomas G, Nally J, Nakhoul NL, Nakhoul GN. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol. 2021 07 15; 22(1):264.
    View in: PubMed
    Score: 0.120
  3. Navaneethan SD, Kirwan JP, Remer EM, Schneider E, Addeman B, Arrigain S, Horwitz E, Fink JC, Lash JP, McKenzie CA, Rahman M, Rao PS, Schold JD, Shafi T, Taliercio JJ, Townsend RR, Feldman HI. Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD. Am J Kidney Dis. 2021 01; 77(1):44-55.
    View in: PubMed
    Score: 0.113
  4. Azem R, Daou R, Bassil E, Anvari EM, Taliercio JJ, Arrigain S, Schold JD, Vachharajani T, Nally J, Na Khoul GN. Serum magnesium, mortality and disease progression in chronic kidney disease. BMC Nephrol. 2020 02 12; 21(1):49.
    View in: PubMed
    Score: 0.109
  5. Patel KK, Shah SY, Arrigain S, Jolly S, Schold JD, Navaneethan SD, Griffin BP, Nally JV, Desai MY. Characteristics and Outcomes of Patients With Aortic Stenosis and Chronic Kidney Disease. J Am Heart Assoc. 2019 02 05; 8(3):e009980.
    View in: PubMed
    Score: 0.101
  6. Airy M, Schold JD, Jolly SE, Arrigain S, Bansal N, Winkelmayer WC, Nally JV, Navaneethan SD. Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation. Am J Nephrol. 2018; 48(1):36-45.
    View in: PubMed
    Score: 0.098
  7. Navaneethan SD, Schold JD, Walther CP, Arrigain S, Jolly SE, Virani SS, Winkelmayer WC, Nally JV. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol. 2018 Jul - Aug; 12(4):1061-1071.e7.
    View in: PubMed
    Score: 0.095
  8. Rincon-Choles H, Jolly SE, Arrigain S, Konig V, Schold JD, Nakhoul G, Navaneethan SD, Nally JV, Rothberg MB. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol. 2017; 46(4):315-322.
    View in: PubMed
    Score: 0.092
  9. Navaneethan SD, Jolly SE, Schold JD, Arrigain S, Nakhoul G, Konig V, Hyland J, Burrucker YK, Dann PD, Tucky BH, Sharp J, Nally JV. Pragmatic Randomized, Controlled Trial of Patient Navigators and Enhanced Personal Health Records in CKD. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1418-1427.
    View in: PubMed
    Score: 0.091
  10. Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Blum MF, Winkelmayer WC, Nally JV. Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease. Kidney Int. 2017 11; 92(5):1272-1281.
    View in: PubMed
    Score: 0.091
  11. Huang H, Jolly SE, Airy M, Arrigain S, Schold JD, Nally JV, Navaneethan SD. Associations of dysnatremias with mortality in chronic kidney disease. Nephrol Dial Transplant. 2017 Jul 01; 32(7):1204-1210.
    View in: PubMed
    Score: 0.091
  12. Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Winkelmayer WC, Nally JV. Diabetes Control and the Risks of ESRD and Mortality in?Patients?With CKD. Am J Kidney Dis. 2017 Aug; 70(2):191-198.
    View in: PubMed
    Score: 0.088
  13. Navaneethan SD, Mandayam S, Arrigain S, Rahman M, Winkelmayer WC, Schold JD. Obstructive and Restrictive Lung Function Measures and CKD: National Health and Nutrition Examination Survey (NHANES) 2007-2012. Am J Kidney Dis. 2016 09; 68(3):414-21.
    View in: PubMed
    Score: 0.084
  14. Navaneethan SD, Schold JD, Huang H, Nakhoul G, Jolly SE, Arrigain S, Dweik RA, Nally JV. Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease. Am J Nephrol. 2016; 43(1):39-46.
    View in: PubMed
    Score: 0.082
  15. Navaneethan SD, Schold JD, Arrigain S, Kirwan JP, Nally JV. Body mass index and causes of death in chronic kidney disease. Kidney Int. 2016 Mar; 89(3):675-82.
    View in: PubMed
    Score: 0.082
  16. Navaneethan SD, Fealy CE, Scelsi AC, Arrigain S, Malin SK, Kirwan JP. A Trial of Lifestyle Modification on Cardiopulmonary, Inflammatory, and Metabolic Effects among Obese with Chronic Kidney Disease. Am J Nephrol. 2015; 42(4):274-81.
    View in: PubMed
    Score: 0.081
  17. Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV, Navaneethan SD. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease. Am J Nephrol. 2015; 41(6):456-63.
    View in: PubMed
    Score: 0.079
  18. Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV, Navaneethan SD. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol. 2015 Jul 07; 10(7):1119-27.
    View in: PubMed
    Score: 0.079
  19. Toledo C, Thomas G, Schold JD, Arrigain S, Gornik HL, Nally JV, Navaneethan SD. Renal resistive index and mortality in chronic kidney disease. Hypertension. 2015 Aug; 66(2):382-8.
    View in: PubMed
    Score: 0.079
  20. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV. Cause-Specific Deaths in Non-Dialysis-Dependent CKD. J Am Soc Nephrol. 2015 Oct; 26(10):2512-20.
    View in: PubMed
    Score: 0.079
  21. Jolly SE, Navaneethan SD, Schold JD, Arrigain S, Konig V, Burrucker YK, Hyland J, Dann P, Tucky BH, Sharp JW, Nally JV. Development of a chronic kidney disease patient navigator program. BMC Nephrol. 2015 May 03; 16:69.
    View in: PubMed
    Score: 0.078
  22. Navaneethan SD, Kirwan JP, Arrigain S, Schold JD. Adiposity measures, lean body mass, physical activity and mortality: NHANES 1999-2004. BMC Nephrol. 2014 Jul 08; 15:108.
    View in: PubMed
    Score: 0.074
  23. Navaneethan SD, Sakhuja A, Arrigain S, Sharp J, Schold JD, Nally JV. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease. Clin Nephrol. 2014 Jul; 82(1):16-25.
    View in: PubMed
    Score: 0.074
  24. Khurana KK, Navaneethan SD, Arrigain S, Schold JD, Nally JV, Shoskes DA. Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis. 2014 Sep; 64(3):367-74.
    View in: PubMed
    Score: 0.073
  25. Jolly SE, Navaneethan SD, Schold JD, Arrigain S, Sharp JW, Jain AK, Schreiber MJ, Simon JF, Nally JV. Chronic kidney disease in an electronic health record problem list: quality of care, ESRD, and mortality. Am J Nephrol. 2014; 39(4):288-96.
    View in: PubMed
    Score: 0.072
  26. Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, Nally JV, Schold JD, Rahman M, Dweik RA. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol. 2014 May; 9(5):855-63.
    View in: PubMed
    Score: 0.072
  27. Crews DC, Scialla JJ, Boulware LE, Navaneethan SD, Nally JV, Liu X, Arrigain S, Schold JD, Ephraim PL, Jolly SE, Sozio SM, Michels WM, Miskulin DC, Tangri N, Shafi T, Wu AW, Bandeen-Roche K. Comparative effectiveness of early versus conventional timing of dialysis initiation in advanced CKD. Am J Kidney Dis. 2014 May; 63(5):806-15.
    View in: PubMed
    Score: 0.072
  28. Taliercio JJ, Schold JD, Simon JF, Arrigain S, Tang A, Saab G, Nally JV, Navaneethan SD. Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J Kidney Dis. 2013 Oct; 62(4):703-10.
    View in: PubMed
    Score: 0.068
  29. Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, Beddhu S, Nally JV. Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol. 2013 Jun; 8(6):945-52.
    View in: PubMed
    Score: 0.067
  30. Navaneethan SD, Schold JD, Arrigain S, Thomas G, Jolly SE, Poggio ED, Schreiber MJ, Sarnak MJ, Nally JV. Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease. Nephrol Dial Transplant. 2012 Aug; 27(8):3228-34.
    View in: PubMed
    Score: 0.063
  31. Liew Y, Rafey MA, Allam S, Arrigain S, Butler R, Schreiber M. Blood pressure goals and arterial stiffness in chronic kidney disease. J Clin Hypertens (Greenwich). 2009 Apr; 11(4):201-6.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)